Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by subaru1ion Apr 22, 2023 7:48pm
210 Views
Post# 35409053

So Pfizer wants to launch 12 NEW drugs in China by 2025, wow

So Pfizer wants to launch 12 NEW drugs in China by 2025, wowthat's launching one NEW drug every 2 months.   Well that boxes in very nicely because the prior Investor Deck (not the current one) indicated cannabinoid API's to be a $25 BILLION DOLLAR MARKET by 2025 as well.   At the rate of the FDA and status of existing U.S. clinical trials, that's makes it an impossibility to obtain that type of growth within the U.S. and especially, on average, 1 NEW drug every 2 months.   But that type of growth for NEW drugs is very realistic when addressing over a 1 billion population in China.   I am so happy that a traditional pharmaceutical company has LABS as a partner.  


<< Previous
Bullboard Posts
Next >>